Literature DB >> 16152598

Cancer risk among patients with multiple sclerosis: a population-based register study.

Nete Munk Nielsen1, Klaus Rostgaard, Søren Rasmussen, Nils Koch-Henriksen, Hans H Storm, Mads Melbye, Henrik Hjalgrim.   

Abstract

Cancer occurrence in patients with multiple sclerosis (MS) has been little studied, but associations with brain tumours, breast cancer, Hodgkin lymphoma and nasopharyngeal carcinoma have been suggested. We took advantage of population-based registers of MS and cancer to assess the risk of cancer following diagnosis of MS. Patients registered in the Danish Multiple Sclerosis Register were linked with the Danish Cancer Register to obtain information on cancer occurrence. The ratio of the observed to the number of expected cancers based on population-based incidence rates, i.e., the standardised incidence ratio (SIR), served as measure of the relative cancer risk. A database comprising all Danish women born after April 1, 1935, with information on all live-born children, was used in the analyses of breast cancer to adjust for reproductive factors. Overall 1,037 cancers were observed in 11,817 MS patients during 153,875 person-years of follow-up vs. an expected number of 1,098 (SIR = 0.94 [95% confidence interval CI: (0.89-1.00)]. The risk of brain tumours and Hodgkin lymphoma was not increased. A 16% overall reduced cancer risk in men with MS was explained by reduced numbers of cancers of the digestive, respiratory and genital organs. Though the overall cancer risk was not increased [SIR = 1.01(0.94-1.09), n = 676], female MS patients had an increased risk of breast cancer [SIR = 1.21 (1.05-1.39), n = 193]. Adjusting for parity and age at first child delivery did not change this risk estimate materially. In general MS patients are not at increased risk of cancer. Women with MS, however, seem to have a small excess risk of breast cancer, which cannot be attributed to reduced parity or delayed first child birth.

Entities:  

Mesh:

Year:  2006        PMID: 16152598     DOI: 10.1002/ijc.21437

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  GPC5 gene and its related pathways in lung cancer.

Authors:  Yafei Li; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

2.  Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States.

Authors:  Jill Koshiol; Tram Kim Lam; Gloria Gridley; David Check; Linda Morris Brown; Ola Landgren
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

Review 3.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

4.  Breast cancer screening barriers and disability.

Authors:  Ana Todd; Alexa Stuifbergen
Journal:  Rehabil Nurs       Date:  2012 Mar-Apr       Impact factor: 1.625

Review 5.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

6.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

Review 7.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

8.  Immune surveillance and lymphoid malignancy in immunocompromised host.

Authors:  Patrick L Stevens; Nishitha M Reddy
Journal:  Am J Blood Res       Date:  2013-05-05

Review 9.  Breast cancer and the immune system.

Authors:  Leanna J Standish; Erin S Sweet; Jeffrey Novack; Cynthia A Wenner; Carly Bridge; Ana Nelson; Mark Martzen; Carolyn Torkelson
Journal:  J Soc Integr Oncol       Date:  2008

Review 10.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.